Checklist for the preparation and review of pain clinical trial publications: A pain-specific supplement to CONSORT

Pain Reports

Volumn 4, Issue 3, 2019, Pages

  Gewandter, Jennifer S ^a   Eisenach, James C ^b,c   Gross, Robert A ^a   Jensen, Mark P ^d   Keefe, Francis J ^e,f   Lee, David A ^g   Turk, Dennis C ^h  

^a UNIVERSITY OF ROCHESTER   (United States)

^b Departments of Anesthesiology and Physiology and Pharmacology   (United States)

^c Departments of Pharmacology   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e Departments of Psychiatry and Behavioral Sciences   (United States)

^f DUKE UNIVERSITY   (United States)

^g NONE   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Reporting checklist

Indexed keywords

EID: 85064425914     PISSN: None     EISSN: 24712531     Source Type: Journal    
DOI: 10.1097/PR9.0000000000000621     Document Type: Article

References (44)

1. Altman D, Bland M. Absence of evidence is not evidence of absence. BMJ 1995; 311: 485.
2. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 1833-40.
3. Borrelli B. The assessment, monitoring, and enhancement of treatment fidelity in public health clinical trials. J Public Health Dent 2011; 71: S52-63.
4. Boutron I, Dutton S, Ravaud P, Altman DG. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 2010; 303: 2058-64.
5. Buckhardt CS, Clark SR, Bennet RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991; 18: 728-33.
6. CleelandC. Brief pain inventory, 1991. Available at: http://www. mdanderson. org/education-and-research/departments-programs-and-labs/departmentsand-divisions/symptom-research/symptom-assessment-tools/brief-paininventory. html. Accessed February 15, 2017.
7. Detsky AS, Sackett DL. When was a "negative" clinical trial big enough? How many patients you needed depends on what you found. Arch Intern Med 1985; 145: 709-12.
8. Dworkin JD, Mckeown A, Farrar JT, Gilron I, Hunsinger M, Kerns RD, McDermott MP, Rappaport BA, Turk DC, Dworkin RH, Gewandter JS. Deficiencies in reporting of statistical methodology in recent randomized trials of nonpharmacologic pain treatments: ACTTION systematic review. J Clin Epidemiol 2016; 72: 56-65.
9. Dworkin RH, Burke LB, Gewandter JS, Smith SM. Reliability is necessary but far from sufficient. Howmight the validity of pain ratings be improved? CJP 2015; 31: 599-602.
10. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J; Immpact. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. PAIN 2005; 113: 9-19.
11. Dworkin RH, Turk DC, Peirce-Sandner S, Burke LB, Farrar JT, Gilron I, Jensen MP, Katz NP, Raja SN, Rappaport BA, Rowbotham MC, Backonja MM, Baron R, Bellamy N, Bhagwagar Z, Costello A, Cowan P, Fang WC, Hertz S, Jay GW, Junor R, Kerns RD, Kerwin R, Kopecky EA, Lissin D, Malamut R, Markman JD, McDermott MP, Munera C, Porter L, Rauschkolb C, Rice AS, Sampaio C, Skljarevski V, Sommerville K, Stacey BR, Steigerwald I, Tobias J, Trentacosti AM, Wasan AD, Wells GA, Williams J, Witter J, Ziegler D. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. PAIN 2012; 153: 1148-58.
12. European Medicines Agency. Guideline on choice of non-inferiority margin. Stat Med 2006; 25: 1628-38.
13. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Adaptive designs in clinical drug development-an Executive Summary of the PhRMA Working Group. J Biopharm Stat 2006; 16: 275-83; discussion 285-91, 293-8, 311-2.
14. Gewandter JS, Dworkin RH, Turk DC, McDermott MP, Baron R, Gastonguay MR, Gilron I, Katz NP, Mehta C, Raja SN, Senn S, Taylor C, Cowan P, Desjardins P, Dimitrova R, Dionne R, Farrar JT, Hewitt DJ, Iyengar S, Jay GW, Kalso E, Kerns RD, Leff R, Leong M, Petersen KL, Ravina BM, Rauschkolb C, Rice AS, Rowbotham MC, Sampaio C, Sindrup SH, Stauffer JW, Steigerwald I, Stewart J, Tobias J, Treede RD, Wallace M, White RE. Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. PAIN 2014; 155: 1683-95.
15. Gewandter JS, McDermott MP, Mckeown A, Smith SM, Pawlowski JR, Poli JJ, Rothstein D, Williams MR, Bujanover S, Farrar JT, Gilron I, Katz NP, Rowbotham MC, Turk DC, Dworkin RH. Reporting of intention-to-treat analyses in recent analgesic clinical trials: ACTTION systematic review and recommendations. PAIN 2014; 155: 2714-9.
16. Gewandter JS, McDermott MP, Mckeown A, Smith SM, Williams MR, Hunsinger M, Farrar J, Turk DC, Dworkin RH. Reporting of missing data and methods used to accommodate them in recent analgesic clinical trials: ACTTION systematic review and recommendations. PAIN 2014; 155: 1871-7.
17. Gewandter JS, Mckeown A, McDermott MP, Dworkin JD, Smith SM, Gross RA, Hunsinger M, Lin AH, Rappaport BA, Rice AS, Rowbotham MC, Williams MR, Turk DC, Dworkin RH. Data interpretation in analgesic clinical trials with statistically nonsignificant primary analyses: an ACTTION systematic review. J Pain 2015; 16: 3-10.
18. Gewandter JS, Smith SM, Mckeown A, Burke LB, Hertz SH, Hunsinger M, Katz NP, Lin AH, McDermott MP, Rappaport BA, Williams MR, Turk DC, Dworkin RH. Reporting of primary analyses and multiplicity adjustment in recent analgesic clinical trials: ACTTION systematic review and recommendations. PAIN 2014; 155: 461-6.
19. Gewandter JS, Smith SM, Mckeown A, Edwards K, Narula A, Pawlowski JR, Rothstein D, Desjardins PJ, Dworkin SF, Gross RA, Ohrbach R, Rappaport BA, Sessle BJ, Turk DC, Dworkin RH. Reporting of adverse events and statistical details of efficacy estimates in randomized clinical trials of pain in temporomandibular disorders: analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks systematic review. J Am Dent Assoc 2015; 146: 246-54. e6.
20. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 1994; 121: 200-6.
21. Hunsinger M, Smith SM, Rothstein D, Mckeown A, Parkhurst M, Hertz S, Katz NP, Lin AH, McDermott MP, Rappaport BA, Turk DC, Dworkin RH. Adverse event reporting in nonpharmacologic, noninterventional pain clinical trials: ACTTION systematic review. PAIN 2014; 155: 2253-62.
22. Ioannidis JP. Why most published research findings are false. PLoS Med 2005; 2: e124.
23. Ioannidis JP, Evans SJ, Gøtzsche PC, O'neill RT, Altman DG, Schulz K, Moher D. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004; 141: 781-8.
24. Juni P, Altman DG, EggerM. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001; 323: 42-6.
25. Katz N. Methodological issues in clinical trials of opioids for chronic pain. Neurology 2005; 65: S32-49.
26. Katz N. Enriched enrollment randomized withdrawal trial designs of analgesics: focus on methodology. Clin J Pain 2009; 25: 797-807.
27. Little RJA, Rubin, DB. Statistical analyses with missing data. New York: John Wiley & Sons, Inc, 1987.
28. Mcquay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched Enrolment with Randomised Withdrawal (EERW): time for a new look at clinical trial design in chronic pain. PAIN 2008; 135: 217-20.
29. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c869.
30. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001; 134: 657-62.
31. Molenbergs G, Kenward MG. Missing data in clincal studies. Chichester, United Kingdom: John Wiley & Sons Ltd., 2007.
32. Moore RA, Wiffen PJ, Eccleston C, Derry S, Baron R, Bell RF, Furlan AD, Gilron I, Haroutounian S, Katz NP, Lipman AG, Morley S, Peloso PM, Quessy SN, Seers K, Strassels SA, Straube S. Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: a new framework for design and reporting. PAIN 2015; 156: 1382-95.
33. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 2012; 308: 2594-604.
34. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12.
35. Senn SJ. Turning a blind eye: authors have blinkered view of blinding. BMJ 2004; 328: 1135-6; author reply 1136.
36. Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med 1986; 105: 429-35.
37. Smith SM, Amtmann D, Askew RL, Gewandter JS, Hunsinger M, Jensen MP, McDermott MP, Patel KV, Williams M, Bacci ED, Burke LB, Chambers CT, Cooper SA, Cowan P, Desjardins P, Etropolski M, Farrar JT, Gilron I, Huang IZ, Katz M, Kerns RD, Kopecky EA, Rappaport BA, Resnick M, Strand V, Vanhove GF, Veasley C, Versavel M, Wasan AD, Turk DC, Dworkin RH. Pain intensity rating training: results from an exploratory study of the ACTTION PROTECCT system. PAIN 2016; 157: 1056-64.
38. Smith SM, Chang RD, Pereira A, Shah N, Gilron I, Katz NP, Lin AH, McDermott MP, Rappaport BA, Rowbotham MC, Sampaio C, Turk DC, Dworkin RH. Adherence to CONSORT harms-reporting recommendations in publications of recent analgesic clinical trials: an ACTTION systematic review. PAIN 2012; 153: 2415-21.
39. Smith SM, Hunsinger M, Mckeown A, Parkhurst M, Allen R, Kopko S, Lu Y, Wilson HD, Burke LB, Desjardins P, McDermott MP, RappaportBA, TurkDC, Dworkin RH. Quality of pain intensity assessment reporting: ACTTION systematic review and recommendations. J Pain 2015; 16: 299-305.
40. Smith SM, Wang AT, Katz NP, McDermott MP, Burke LB, Coplan P, Gilron I, Hertz SH, Lin AH, Rappaport BA, Rowbotham MC, Sampaio C, Sweeney M, Turk DC, Dworkin RH. Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTTION systematic review and recommendations. PAIN 2013; 154: 997-1008.
41. Turk DC, Dworkin RH, Mcdermott MP, Bellamy N, Burke LB, Chandler JM, Cleeland CS, Cowan P, Dimitrova R, Farrar JT, Hertz S, Heyse JF, Iyengar S, Jadad AR, Jay GW, Jermano JA, Katz NP, Manning DC, Martin S, Max MB, Mcgrath P, Mcquay HJ, Quessy S, Rappaport BA, Revicki DA, Rothman M, Stauffer JW, Svensson O, White RE, Witter J. Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials. PAIN 2008; 139: 485-93.
42. Tuttle AH, Tohyama S, Ramsay T, Kimmelman J, Schweinhardt P, Bennett GJ, Mogil JS. Increasing placebo responses over time in U. S. clinical trials of neuropathic pain. PAIN 2015; 156: 2616-26.
43. U. S. Health and Human Services. Adaptive design clinical trials for drugs and biologicals: draft guidance, 2010. Available at: http://www. fda. gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm201790. pdf. Accessed November 22, 2016.
44. U. S. Health and Human Services. Guidance for industry: non-inferiority trials, 2010. Available at: http://www. fda. gov/downloads/Drugs/./Guidances/UCM202140. pdf. Accessed November 22, 2016.